Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282936 | 0.90 | ALDH1A1 (0.48) | ALDH1A1OPRD1OPRM1OPRK1LMNA | |
| SCHEMBL14282935 | 0.85 | ALDH1A1 (0.43) | ALDH1A1OPRD1OPRM1OPRK1DRD2 | |
| SCHEMBL14198340 | 0.79 | SETD7 (0.57) | ALDH1A1OPRD1OPRM1OPRK1P2RX7 | |
| SCHEMBL4563119 | 0.79 | OPRD1 (0.54) | ALDH1A1OPRD1OPRM1OPRK1HTR2A | |
| SCHEMBL4081229 | 0.78 | OPRD1 (0.50) | ALDH1A1OPRD1OPRM1OPRK1P2RX7 | |
| SCHEMBL14282934 | 0.77 | DRD2 (0.47) | ALDH1A1OPRD1OPRM1OPRK1LMNA | |
| SCHEMBL14198374 | 0.76 | SETD7 (0.58) | ALDH1A1OPRD1OPRM1OPRK1P2RX7 | |
| SCHEMBL4693876 | 0.76 | OPRD1 (0.48) | ALDH1A1OPRD1OPRM1OPRK1LMNA | |
| SCHEMBL65060 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAHPGDTSHR | |
| SCHEMBL12014429 | 0.74 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1443929-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7317026-B2 | Sleep disorders; side effect reduction ; antihistamine antagonist | HYPNION, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7189757-B2 | Treatment of sleep disorders using CNS target modulators | HYPNION, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2005103041-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HYPNION, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2003032912-A9 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1443929-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040142972-A1 | CNS target modulators | HYPNION, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003032912-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009730-A1 | Treatment of cns disorders using cns target modulators | HCRTR2, CNR2, CNR1 | ALDH1A1 1623/4885OPRD1 645/4885OPRM1 535/4885 |
| US-20030187021-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, CNR2, CNR1 | ALDH1A1 1623/4885OPRD1 645/4885OPRM1 535/4885 |
| US-20050080265-A1 | Treatment of CNS disorders using CNS target modulators | HCRTR2, HRH3, HCRTR1 | ALDH1A1 2710/4885OPRD1 554/4885OPRM1 382/4885 |
| US-20040142972-A1 | CNS target modulators | HCRTR2, CNR2, CNR1 | ALDH1A1 1316/4885OPRD1 399/4885OPRM1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.